DiaMedica Therapeutics Inc.
At Close: 4:00 PM
Pre Market: 6:59 AM
DMAC Stock Price Graph
DMAC Stock Price Today
DiaMedica Therapeutics Inc. (DMAC) stock declined over -1.06% intraday to trade at $2.81 a share on NASDAQ. The stock opened with a loss of -5.99% at $2.67 and touched an intraday high of $2.90, falling -1.06% against the last close of $2.84. The DiaMedica Therapeutics Inc. in stock market went to a low of $2.51 during the session.
DMAC Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
DMAC Stock Price History Chart
Two Carlson ParkwayMinneapolis, MN 55447US
Contact #:763 612 6755
Sales or RevenueN/A
5Y Sales ChangeN/A
Fiscal Year EndsDec. 2022
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Frequently Asked Questions
What is the current DiaMedica Therapeutics Inc. (DMAC) stock price?
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock price is $2.81 in the last trading session. During the trading session, DMAC stock reached the peak price of $2.90 while $2.51 was the lowest point it dropped to. The percentage change in DMAC stock occurred in the recent session was -1.06% while the dollar amount for the price change in DMAC stock was -$0.03.
DMAC's industry and sector of operation?
The NASDAQ listed DMAC is part of Biotechnology industry that operates in the broader Healthcare sector. DiaMedica Therapeutics Inc. , a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
Who are the executives of DMAC?
Mr. Dietrich John Pauls MBA
Pres, Chief Executive Officer & Director
Mr. Scott B. Kellen C.A.
Chief Financial Officer & Company Sec.
Ms. Julie VanOrsdel Daves CCRP
Senior Vice President of Clinical Devel. Operations
Mr. Dietrich John Pauls MBA
Pres, CEO & Director
How DMAC did perform over past 52-week?
DMAC's closing price is 0.49% higher than its 52-week low of $1.12 where as its distance from 52-week high of $3.17 is -0.37%.
How many employees does DMAC have?
Number of DMAC employees currently stands at 16.00. DMAC operates from Two Carlson Parkway</br>Minneapolis, MN 55447</br>US.
Link for DMAC official website?
Official Website of DMAC is: https://www.diamedica.com
How do I contact DMAC?
DMAC could be contacted at phone #763 612 6755 and can also be accessed through its website. DMAC operates from Two Carlson Parkway</br>Minneapolis, MN 55447</br>US.
How many shares of DMAC are traded daily?
DMAC stock volume for the day was 76102.00 shares. The average number of DMAC shares traded daily for last 3 months was 29.75 Thousands.
What is the market cap of DMAC currently?
The market value of DMAC currently stands at $52.64 Million with its latest stock price at $2.81 and 26.44 Million of its shares outstanding.